All News

Pharmaceutical Executive

Understanding how drugs are bought and paid for has always been a bit complicated. People used to say that pharma had two customers-physicians and patients. Only one of them used the drug, and neither of them knew the price. My, how times have changed. Now the industry has so many customers, it needs to stop and get to know them all over again. And that's at a time when drugs worth tens of billions of dollars are going off patent. To map pharma's shifting landscape, Pharm Exec convened a group of top market researchers to discuss the issues shaping an evolving industry. Topics ranged far and wide, from the advent of Medicare Part D, to the new focus on adherence, the role of international markets, even the brave new world of marketing to seniors' children.

Pharmaceutical Executive

Given the high volume of rep interactions with healthcare professionals, companies must work toward achieving a fully integrated system that collects data from across the entire enterprise.

Pharmaceutical Executive

Before a pharmaceutical company dispatches a sales rep to a medical practice, the marketing department learns some basic facts about the physician: how many new prescriptions she's written, how many refills, and how much upside prescribing growth she might generate. What the rep usually doesn't know: who else-nurse practitioners and physician assistants-prescribes medications in the office, at a nearby clinic, or sometimes in a separate practice just down the hall.

PED_article_logo-309932-1408686954097.gif

Pharmaceutical Executive

An analysis of Merck’s clinical trial data for Singular (montelukast) indicates that obese people may respond to asthma treatments differently than lean people. A University of Michigan professor explains his recently published paper.

Pharmaceutical Executive

In 2004, US growth hormone sales reached nearly $711 million. But harsh restrictions on growth hormone treatments and their abuse as "lifestyle drugs" have injected controversy into the market. How can pharma ensure that its marketing efforts for products that help millions of children and adults reach the right targets?

Pharmaceutical Executive

As 2006 gets under way, changes in the industry are creating new opportunites for product managers, along with a landslide of challenges. Blockbuster drugs that represent 50 to 60 percent of pharmaceutical sales will come off patent in the next few years, and with consumer awareness now greater than ever, product managers need to work even harder to keep up. The articles in this volume address these growing concerns.

Pharmaceutical Executive

Imagine a person sitting alone in his living room suffering through a pounding migraine, while the rest of his family sits together around the kitchen table. He wants to join them, but his symptoms render him motionless. Now, imagine he has the choice to take two different drugs that promise to alleviate symptoms of his migraine. Drug A promises to help at the source of the problem by decreasing the frequency of swollen blood vessels around the brain, while drug B promises migraine-free days with more time to spend with the family. What do you think he would choose?

Pharmaceutical Executive

At the Division of Drug Marketing, Advertising, and Communications (DDMAC), our goal is to assure that prescription drug promotion is not false or misleading, and that it presents a balanced picture of a drug's risks, as well as its benefits.

Pharmaceutical Executive

Pharma companies spend the most money looking at what their competitors have already done. Here, three companies explain how competitive intelligence should work.

Pharmaceutical Executive

Attacking articles in medical journals, those ghostwritten by professional medical writers paid by pharmaceutical companies, is the media's latest attempt to taint anything supported, promoted, or approved by Big Pharma.

PED_article_logo-301532-1408683917411.gif

Pharmaceutical Executive

An entertaining Internet program that allows Americans to see where a dollar goes after they spend it, helped scientists develop a formula for how infectious diseases spread geographically in United States.

PED_article_logo-301530-1408683919870.gif

Pharmaceutical Executive

Upcoming competition, a weak pipeline, and existing marketing agreements limit the pool of prospective buyers, experts say.

PED_article_logo-283405-1408689004552.gif

Pharmaceutical Executive

Observing drug candidates in humans early in the development process could save investigators time and money, experts say.

PED_article_logo-279282-1408682423223.gif

Pharmaceutical Executive

Two experts are split over the importance of research on a gene linked with a rare genetic type of Parkinson’s disease. One thinks it could hold the key to new treatment. The other thinks it is too rare to be relevant.

PED_article_logo-279279-1408682426233.gif

Pharmaceutical Executive

Q&A with Dr. Allan Brett, professor at the University of South Carolina and director of the General Internal Medicine division. He authored a recent perspective about on-demand Tamiflu prescriptions in the New England Journal of Medicine.

Pharmaceutical Executive

Often, post-approval marketing studies don't materialize because drug companies question their value. Independent review of the need for such studies would address pharma's concern that they may be warranted.

Pharmaceutical Executive

Witnessing an industry's wild ride is perhaps the best reason to work for a business magazine. You've given us 25 years of excitement. And we plan to pay you back.

Pharmaceutical Executive

There was a time when Merck was looked upon as the granddaddy of all pharma companies. As the self-proclaimed oldest pharmaceutical and chemical company in the world, people wanted to work at Merck for its sterling reputation, excellent products, and job security.